Nika Pharmaceuticals, Inc. reported a net loss of $46,077 for the nine months ended September 30, 2026, compared to a loss of $39,309 in the prior year period. The company remains in a pre-revenue stage with a total stockholders' deficit of $343,705 and is primarily funded through loans from related parties.
ACCESS Newswire reported Q3 2026 financial results with revenue of $5.5 million and a gross margin expansion to 75%. The company achieved an Adjusted EBITDA margin of 15% and positive cash flow from operations of $469,000 despite a slight year-over-year revenue decrease due to lower press release volumes.
Term
Q3 2026
“Our third quarter demonstrated the resilience of our business model in a rapidly evolving news distribution market. We increased the number of active customers by 14% year-over-year, expanded gross margin to 75%, grew average revenue per release, and built continued momentum and revenue contribution from our Insight & Analytics, social monitoring and PRO offerings.”
Brian R. Balbirnie, ACCESS Newswire’s Founder and Chief Executive Officer
“In October we streamlined our organization across sales, development, editorial and operations, which we expect to generate annualized savings over $1.5 million, with a partial benefit in the fourth quarter and the full benefit beginning in the first quarter of 2027 and beyond.”
Brian R. Balbirnie, ACCESS Newswire’s Founder and Chief Executive Officer
Csquare, Inc. reported a net loss of $88.1 million for the third quarter of 2026, compared to a $29.8 million loss in the prior year, despite a 25.6% increase in revenues to $302.3 million. The company completed its initial public offering during the quarter, raising approximately $1.14 billion and converting its member's interest into common stock.
Terrestrial Energy reported its Q3 2026 financial results, highlighting its selection as the advanced nuclear technology supplier for Ameresco's project at the U.S. Army’s Aberdeen Proving Ground. The company ended the quarter with $276.3 million in cash and no debt while completing its 2026 guidance for NRC topical report submissions.
Term
Q3 2026
“Our selection for Ameresco’s project with the U.S. Army extends our commercial pipeline into the federal government and defense, and with our Thermal and Electric Facility Topical Report, we delivered on our guidance of at least three submissions to the NRC this year.”
Simon Irish, Chief Executive Officer of Terrestrial Energy
“We are focused on the race to fleet deployment, and on delivering nuclear power at fleet scale. The world needs innovative nuclear plants for new sources of clean, firm, affordable energy, and those fundamentals continue to strengthen supporting our business plan.”
Simon Irish, Chief Executive Officer of Terrestrial Energy
EquipmentShare.com Inc filed its Q3 2026 10-Q reporting a significant increase in accounts receivable from $748 million at year-end 2025 to $1.154 billion as of September 30, 2026. The company continues to focus on its 'OWN Program' capital-light fleet growth model and its T3 cloud-based platform while maintaining a cash balance of $359 million.
Intelligent Bio Solutions Inc. reported a net loss of $2.67 million for the quarter ended September 30, 2026, an improvement from the $2.99 million loss in the prior year. Revenue grew 25% to $1.39 million, while the company strengthened its liquidity position with cash and cash equivalents increasing to $5.93 million, primarily through financing activities.
Dominari Holdings reported Q3 2026 revenue of $16.4 million, a 69% decrease year-over-year primarily due to lower underwriting and commission revenue. Despite the revenue decline, the company narrowed its sequential net loss to $1.9 million through a 65% reduction in operating expenses and highlighted a 341% increase in annual recurring revenue (ARR) to $3.6 million.
KULR Technology Group reported Q3 2026 revenue of $7.4 million, a 197% year-over-year increase driven by a nearly fourfold jump in product sales. The company completed its exit from Bitcoin mining, resulting in a $15.8 million non-recurring gain and a cash balance of $54.5 million with zero debt. Management also implemented a reduction in force expected to save $4 million annually as it shifts focus toward its KULR ONE battery platform.
Term
Q3 2026
“In the third quarter, we delivered on the three measures that matter for 2026: product revenue growth, gross margin improvement and cost discipline. Product sales nearly quadrupled year-over-year, and the growth came from our KULR ONE platform. Gross margin returned to positive territory, though it is not yet where this business can run. We completed our exit from Bitcoin, repaid our only debt and ended the quarter with $54.5 million in cash.”
Michael Mo, Founder and CEO of KULR Technology Group
Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.
Term
Q3 2026
“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”
Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
KULR Technology Group reported a significant revenue increase to $7.4 million for the third quarter of 2026, up from $2.5 million in the prior year period. Despite this growth, the company realized a net loss of $46.5 million for the first nine months of 2026, largely driven by a $15.6 million decrease in the fair value of digital assets and increased research and development expenses.
Tyra Biosciences reported a net loss of $51.1 million for the third quarter of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet during the first nine months of 2026, raising over $524 million through an at-the-market offering and a separate issuance of common stock and pre-funded warrants.
Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.
TriSalus Life Sciences reported a net loss of $16.5 million for the nine months ended September 30, 2026, an improvement from a $29.5 million loss in the prior year period. Revenue grew to $33.2 million, while the company strengthened its balance sheet with cash and cash equivalents increasing to $41.1 million.
For the three months ended October 2, 2026, Aviat Networks reported a net loss of $2.8 million on total revenues of $102.0 million, a decrease from the $107.3 million in revenue and $0.2 million in net income reported in the prior year period. The decline was driven by lower product and service sales and increased cost of revenues relative to sales, resulting in a gross profit margin decrease from 33.2% to 29.6%.
Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.
“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million, representing 11.3% year-over-year growth driven by increased TriNav unit sales. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million and highlighted recent FDA clearance for its TriNav Advance system.
“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice.”
Mary Szela, President and Chief Executive Officer
“Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists.”
Aviat Networks reported fiscal 2027 first quarter results with total revenues of $102.0 million, a 5% decrease year-over-year. Despite the revenue dip, the company achieved record first-quarter bookings of over $150 million, resulting in a book-to-bill ratio of 1.5. The company reported a GAAP net loss of $2.8 million but maintained a non-GAAP net income of $1.5 million.
Jerash Holdings reported fiscal 2027 second quarter revenue of $50.3 million, a 19.8% increase year-over-year, driven by higher shipments to U.S. customers. Net income rose significantly to $2.2 million compared to $479,000 in the prior-year period, aided by automation-related efficiency gains and disciplined cost controls. The company issued Q3 revenue guidance of $49 million to $51 million and noted that production facilities are fully booked through June 2027.
Term
Q2 2027
“We delivered a strong quarter of performance, achieving meaningful growth in both revenue and profitability. Over the past several months, we have navigated logistics challenges across the Middle East, including higher import transportation costs driven by regional shipping disruptions and ongoing uncertainty. Despite these headwinds, we expanded margins through strategic early purchases of raw materials, disciplined cost controls, reduced waste, and enhanced operational efficiencies through automation initiatives.”
Sam Choi, Jerash’s chief executive officer
“Our production facilities are fully booked through June 2027, and order in-flow remains strong. To support continued growth and capitalize on new business opportunities, we are actively seeking ways to expand capacity. Renovations at our most recently acquired facility, along with the construction of a third satellite factory supported by the Jordanian government, are expected to be completed by September 2027. Together, these projects are anticipated to increase our production capacity by approximately 15-20 percent, positioning us to meet growing customer demand and support Jerash’s long-term growth objectives.”
Tyra Biosciences reported third quarter 2026 financial results, highlighting a cash position of $700.5 million following a $400 million financing. The company is advancing its '3x3 strategy' for dabogratinib, including positive initial Phase 2 results in NMIBC and preparations for Phase 3 development.
“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients.”
Todd Harris, PhD, President and Chief Executive Officer
“With a strengthened balance sheet following our $400 million financing, TYRA is entering its next phase of growth from a position of strength. We now have the financial resources to advance our dabogratinib 3x3 strategy through late-stage clinical development.”
Todd Harris, PhD, President and Chief Executive Officer
Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.
Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.
Term
Q3 2026
“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”
Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics
“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”
Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics
PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.
Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.
PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, primarily driven by a non-cash loss related to warrant liabilities. The company ended the period with $108.5 million in cash, bolstered by a $50 million public offering in August, which is expected to fund operations into early 2028. Key clinical progress includes the completion of enrollment for the rezatapopt Phase 2 ovarian cancer cohort with an NDA submission planned for Q1 2027.
Term
Q3 2026
“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”
David Mack, Ph.D., President and Chief Executive Officer
Lion Copper Corp. reported a net loss of $10.2 million for the nine months ended September 30, 2026, though it achieved a small net income of $0.3 million in the third quarter. The company's cash position significantly improved to $21.2 million following funding activities related to the Nuton LLC earn-in agreement, though management continues to express substantial doubt about the company's ability to continue as a going concern.
Paysign, Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $87.1 million compared to $59.3 million in the prior year, driven largely by a doubling of Pharma industry revenue. Net income for the nine-month period rose to $18.9 million, up from $6.2 million in 2025, reflecting improved operating leverage and higher interest income.
Alliance Laundry Holdings reported Q3 2026 net revenues of $461 million, a 5% increase year-over-year driven by volume and pricing benefits in North America. The company raised its full-year Adjusted EBITDA growth guidance to approximately 10% and reduced net leverage to 2.25x following $45 million in debt repayment.
Term
Q3 2026
“Our third quarter results reflect our deep commitment to customers and the strength, resilience and non-discretionary nature of our business model. We continue to invest in our business by expanding our connected equipment platform, deepening our distributor partnerships, and supporting the businesses, operators and people who count on our products every day.”
HIVE Digital Technologies reported Q2 fiscal 2027 revenue of $84.9 million, driven by a 70% year-over-year increase in AI GPU (HPC) revenue to $8.8 million. Despite stable revenue, the company reported a GAAP net loss of $78.7 million due to significant non-cash charges, including $54.9 million in depreciation and a $31.2 million impairment on mining equipment.
Term
Q2 2027
“Our digital infrastructure platform combines established Bitcoin mining operations with a growing AI computing business. Revenue was broadly stable year over year despite a 27% decline in Bitcoin prices, while HPC revenue increased more than 70%.”
Kalaris Therapeutics reported third quarter 2026 financial results, ending the period with $82.9 million in cash and marketable securities. The company announced a delay in its Phase 1b/2 study of TH103 for nAMD due to a manufacturing supply interruption, with preliminary data now expected in the second half of 2027. Despite the delay, the company successfully completed a technology transfer to a commercial-scale manufacturer and extended its cash runway into 2028.
Term
Q3 2026
“Kalaris made meaningful progress in the third quarter. We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”
Xilio Therapeutics reported 7,063,982 shares of common stock outstanding as of November 6, 2026. The company highlights its reliance on strategic collaborations with AbbVie and Gilead, and notes potential gross proceeds of $36.2 million in Q4 2026 from the exercise of Series C warrants.